RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea. The high dose of the gene therapy – which is designed to express both aflibercept and an RNA interference (RNAi ...

Bayer's AI Innovation Platform (AIIP), powered by Google Cloud technology, streamlines the development of AI-driven medical ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

mRNA vaccines, used for infectious diseases and cancer, have already administered more than 29 million doses globally by 2024 ... positioning the industry as a high-growth space despite its ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

The company is running two phase 3 trials – COAST and ShORe – which are testing the drug in combination with Eylea (aflibercept ... in a single-ascending dose phase 1 study.

Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study suggests that supplementing it in high doses could help reduce symptoms.

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...